<?xml version='1.0' encoding='utf-8'?>
<record xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
			<header>
				<identifier>oai:aavptbiennial-ojs-tamu.tdl.org:article/66</identifier>
				<datestamp>2022-06-28T19:19:14Z</datestamp>
				<setSpec>aavptbiennial:S2</setSpec>
			</header>
			<metadata>
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Pharmacokinetics of oral and intravenous administration of trimethoprim-sulfamethoxazole in Rhode Island Red chickens (Gallus gallus domesticus)</dc:title>
	<dc:creator xml:lang="en">Stafford, Emma G.</dc:creator>
	<dc:creator xml:lang="en">Petritz, Olivia A.</dc:creator>
	<dc:creator xml:lang="en">Thomson, Andrea</dc:creator>
	<dc:creator xml:lang="en">Baynes, Ronald E.</dc:creator>
	<dc:creator xml:lang="en">Flammer, Keven</dc:creator>
	<dc:subject xml:lang="en">trimethoprim-sulfamethoxazole</dc:subject>
	<dc:subject xml:lang="en">Rhode Island Red chicken</dc:subject>
	<dc:subject xml:lang="en">backyard chicken</dc:subject>
	<dc:subject xml:lang="en">pharmacokinetics</dc:subject>
	<dc:description xml:lang="en">Trimethoprim-sulfamethoxazole (TMP-SMZ), is a broad-spectrum antibiotic.&amp;nbsp;&amp;nbsp;While TMP-SMZ is not FDA approved for use in laying hens in the United States, its use is also not prohibited by 21CFR§530.41.&amp;nbsp;Fifteen 3-year old Rhode Island Red hens were deemed healthy based on a complete physical exam, plasma biochemistries, and packed cell volumes.&amp;nbsp;A single dose crossover study was performed using the five hens. Initially, 5 birds each received TMP-SMZ (Aurobindo Pharma USA Inc., Dayton, NY) as a single intravenous dose of 96 mg/kg (16mg/kg trimethoprim and 80mg/kg sulfamethoxazole). Following a 14-day washout period, the same dose was administered orally to the same birds. Plasma SMZ-TMP concentrations were measured by Ultra-High-Pressure Liquid Chromatography-Mass Spectrometry (UPLC-MS) and pharmacokinetic analysis of both IV and oral data was best fit to a non-compartmental model. After PO administration, trimethoprim had a mean Cmax, Tmax, and AUC of 2.1 μg/ml, 3.6 hr, and 43.82 hr* μg/ml, respectively, as well as a terminal half-life of 13.73 hr. PO sulfamethoxazole had a mean Cmax, Tmax, and AUC of 67.06 μg/ml, 5 hr, and 1337.61, respectively, as well as a terminal half-life of 6.62 hr. The bioavailability of TMP was 89.5% and 54.6% for SMZ.</dc:description>
	<dc:publisher xml:lang="en">AAVPT Biennial Symposia</dc:publisher>
	<dc:date>2019-08-23</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://aavptbiennial-ojs-tamu.tdl.org/aavptbiennial/article/view/66</dc:identifier>
	<dc:source xml:lang="en">AAVPT Biennial Symposia; 21st Biennial Symposium; 47</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://aavptbiennial-ojs-tamu.tdl.org/aavptbiennial/article/view/66/61</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2019 American Academy of Veterinary Pharmacology and Therapeutics</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		
